Meredith Harris1, Charles Varnell2, Veronica Taylor3, Susan Tulley Nehus4, Bin Zhang5, Elif Erkan6. 1. Division of Nephrology & Hypertension, Cincinnati Children's Hospital Medical Center, Cincinnati, OH. Electronic address: Meredith.harris@cchmc.org. 2. Division of Nephrology & Hypertension, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; University of Cincinnati College of Medicine, Cincinnati, OH; James M. Anderson Center for Health Systems Excellence, Cincinnati, OH. 3. Division of Nephrology, University of Nebraska Medical Center and Children's Hospital and Medical Center, Omaha, NE. 4. Division of Nephrology & Hypertension, Cincinnati Children's Hospital Medical Center, Cincinnati, OH. 5. University of Cincinnati College of Medicine, Cincinnati, OH; Division is Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH. 6. Division of Nephrology & Hypertension, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; University of Cincinnati College of Medicine, Cincinnati, OH.
Abstract
OBJECTIVE: Hypervitaminosis A is well-described but overlooked in chronic kidney disease (CKD) and has been associated with hypercalcemia, contributing to mineral bone disease. Our objective is to assess prevalence of hypervitaminosis A and its association with bone health in an advanced-CKD population. METHODS: We performed a retrospective review of 58 children with CKD 4-5 to examine the association between vitamin A levels and bone health and compared these values between a primarily formula-fed (FF) and nonprimarily formula-fed cohort (NFF). RESULTS: Fifty-six of 58 patients (97%) had hypervitaminosis A with a mean vitamin A level of 1,475 ± 597 mcg/dL. When compared with the upper limit of normal vitamin A level for age, the FF group's vitamin A level was 2.9x upper limit of normal and the NFF group's vitamin A level was 2.2x upper limit of normal (P = .02). The mean calcium level was 10.3 mg/dL in the FF group and 9.8 mg/dL in the NFF group (P = .057). Percent of patients lower than, within, or greater than goal parathyroid hormone range was statistically significant with 15 (62%) of the FF group lower than goal and 16 (72%) of the NFF cohort greater than goal (P = .006). CONCLUSIONS: We concluded vitamin A and calcium levels are higher in the FF versus the NFF population. FF patients are more likely to have parathyroid hormone levels lower than the goal range, placing them at risk for adynamic bone disease. We recommend monitoring vitamin A levels as part of routine nutritional assessments and dietary interventions to prevent hypervitaminosis A to improve bone health in late CKD.
OBJECTIVE: Hypervitaminosis A is well-described but overlooked in chronic kidney disease (CKD) and has been associated with hypercalcemia, contributing to mineral bone disease. Our objective is to assess prevalence of hypervitaminosis A and its association with bone health in an advanced-CKD population. METHODS: We performed a retrospective review of 58 children with CKD 4-5 to examine the association between vitamin A levels and bone health and compared these values between a primarily formula-fed (FF) and nonprimarily formula-fed cohort (NFF). RESULTS: Fifty-six of 58 patients (97%) had hypervitaminosis A with a mean vitamin A level of 1,475 ± 597 mcg/dL. When compared with the upper limit of normal vitamin A level for age, the FF group's vitamin A level was 2.9x upper limit of normal and the NFF group's vitamin A level was 2.2x upper limit of normal (P = .02). The mean calcium level was 10.3 mg/dL in the FF group and 9.8 mg/dL in the NFF group (P = .057). Percent of patients lower than, within, or greater than goal parathyroid hormone range was statistically significant with 15 (62%) of the FF group lower than goal and 16 (72%) of the NFF cohort greater than goal (P = .006). CONCLUSIONS: We concluded vitamin A and calcium levels are higher in the FF versus the NFF population. FF patients are more likely to have parathyroid hormone levels lower than the goal range, placing them at risk for adynamic bone disease. We recommend monitoring vitamin A levels as part of routine nutritional assessments and dietary interventions to prevent hypervitaminosis A to improve bone health in late CKD.
Authors: Dagmara Borzych; Lesley Rees; Il Soo Ha; Annabelle Chua; Patricia G Valles; Maria Lipka; Pedro Zambrano; Thurid Ahlenstiel; Sevcan A Bakkaloglu; Ana P Spizzirri; Laura Lopez; Fatih Ozaltin; Nikoleta Printza; Pankaj Hari; Günter Klaus; Mustafa Bak; Andrea Vogel; Gema Ariceta; Hui Kim Yap; Bradley A Warady; Franz Schaefer Journal: Kidney Int Date: 2010-09-01 Impact factor: 10.612
Authors: H Ziólkowska; M Pańiczyk-Tomaszewska; A Debiński; Z Polowiec; A Sawicki; M Sieniawska Journal: Acta Paediatr Date: 2000-06 Impact factor: 2.299
Authors: Sevcan A Bakkaloglu; Katherine Wesseling-Perry; Renata C Pereira; Barbara Gales; He-Jing Wang; Robert M Elashoff; Isidro B Salusky Journal: Clin J Am Soc Nephrol Date: 2010-07-15 Impact factor: 8.237
Authors: Craig E Gordon; Ethan M Balk; Bryan N Becker; Peter A Crooks; Bertrand L Jaber; Cynda A Johnson; Maureen A Michael; Brian J G Pereira; Katrin Uhlig; Adeera Levin Journal: Am J Kidney Dis Date: 2008-11 Impact factor: 8.860
Authors: Olga Patricia García; Dolores Ronquillo; María Del Carmen Caamaño; Mariela Camacho; Kurt Zane Long; Jorge L Rosado Journal: Nutr Metab (Lond) Date: 2012-06-15 Impact factor: 4.169
Authors: Vikte Lionikaite; Petra Henning; Christina Drevinge; Furqan A Shah; Anders Palmquist; Pernilla Wikström; Sara H Windahl; Ulf H Lerner Journal: FASEB J Date: 2019-01-22 Impact factor: 5.191